Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imzokitug plus pumitamig and platinum-doublet chemotherapy versus pumitamig plus platinum-doublet chemotherapy in first-line advanced or metastatic NSCLC
2026-525170-19-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Imzokitug + pumitamig + platinum-doublet chemotherapy with Pumitamig + platinum-doublet chemotherapy (2 arms). Primary endpoint: Objective response rate. Planned start Sep 2026; status: authorised.
02
Drugs
imzokitugpumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2026-525170-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525170-19-00.